CN118021803A - Anti-aging and anti-inflammatory composition containing ergothioneine, and preparation method and application thereof - Google Patents

Abstract

The invention provides an ergothioneine-containing composition for delaying aging and resisting inflammation, which comprises the following components in parts by weight: 0.5-10 parts by weight of ergothioneine and 0.5-10 parts by weight of component a; the component a is at least one of beta-carotene or astaxanthin; the components have obvious synergistic effect, can delay aging, resist skin photoaging, resist skin inflammation, and improve dermatitis and skin sensitivity redness.

Description

An anti-aging and anti-inflammatory composition containing ergothioneine, a preparation method and its use

Technical Field

The invention relates to the technical field of medicines, and in particular to an ergothioneine-containing composition for delaying aging and resisting inflammation, a preparation method and use thereof.

Background technique

Aging is a natural process characterized by a slowdown in human functions. The appearance of aging is mainly manifested in skin aging, dryness, wrinkles, sagging, etc. Aging is irreversible, but the aging process can be slowed down. Skin aging mainly includes intrinsic aging and exogenous aging. Exogenous aging refers to aging changes in the skin caused by environmental factors. Because it is mainly affected by ultraviolet (UV) radiation, it is also called photoaging. Unlike intrinsic aging, photoaging can be controlled to a certain extent because it is the result of external factors. Photoaging affects areas exposed to the sun, and its clinical characteristics are fine and coarse wrinkles, roughness, dryness, sagging, and changes in pigmentation. In the past few decades, anti-aging strategies have been developed to combat the signs and functional disorders of skin aging.

Sensitive skin refers specifically to a highly reactive state of the skin under physiological or pathological conditions, mainly occurring on the face. Clinically, the skin is prone to subjective symptoms such as burning, stinging, itching, and tightness when stimulated by physical, chemical, mental and other factors, with or without objective signs such as erythema, scaling, and capillary dilation. Staying up late, high stress, and improper use of cosmetics are the main factors causing sensitive skin. The mechanism of sensitive skin formation mainly includes damaged skin barrier, discomfort mediated by the nervous system, immune response causing multiple symptoms, vascular dysfunction, etc. The mechanism of action is complex, and each mechanism is not isolated, and one move affects the whole body.

Summary of the invention

Therefore, the technical problem to be solved by the present invention is to provide an anti-aging and anti-inflammatory composition containing ergothioneine, a preparation method and use thereof.

To this end, the present invention provides the following technical solutions:

An ergothioneine-containing anti-aging and anti-inflammatory composition comprises the following components in parts by weight: 0.5-10 parts by weight of ergothioneine and 0.5-10 parts by weight of component a; component a is at least one of beta-carotene and astaxanthin.

Optionally, the following components in parts by weight are included: 1.6 parts by weight of ergothioneine and 1.7 parts by weight of component a.

Optionally, the composition further comprises the following components in parts by weight: at least one of 50-1000 parts by weight of collagen peptide, 2-200 parts by weight of ceramide, and 5-500 parts by weight of sodium hyaluronate.

Optionally, the composition further comprises the following components in parts by weight: at least one of 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin, and 2-200 parts by weight of niacinamide.

Optionally, the invention further comprises the following components in parts by weight: at least one of 0.01-1 parts by weight of copper oxide and 2-15 parts by weight of zinc citrate.

Optionally, the invention further comprises the following components in parts by weight: 100-500 parts by weight of glutathione.

Optionally, the following components are included in parts by weight:

1.6 parts by weight of ergothioneine, 1.7 parts by weight of beta-carotene, and 20 parts by weight of ceramide;

Or, 0.5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 635 parts by weight of collagen peptide, and 265 parts by weight of glutathione;

Or, 10 parts by weight of ergothioneine, 0.5 parts by weight of beta-carotene, 200 parts by weight of ceramide, and 100 parts by weight of vitamin E;

Or, 10 parts by weight of ergothioneine, 10 parts by weight of beta-carotene, 50 parts by weight of collagen peptide, and 500 parts by weight of glutathione;

Or, 5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 5 parts by weight of sodium hyaluronate, 0.5 parts by weight of vitamin E, and 30 parts by weight of biotin;

Or, 1 part by weight of ergothioneine, 0.5 part by weight of astaxanthin, 2 parts by weight of ceramide, 200 parts by weight of vitamin C, and 5 parts by weight of biotin;

Or, 3.2 parts by weight of ergothioneine, 5.36 parts by weight of astaxanthin, 2.6 parts by weight of ceramide, 15 parts by weight of zinc citrate, and 1 part by weight of copper oxide;

Or, 1.69 parts by weight of ergothioneine, 1.482 parts by weight of beta-carotene, 834 parts by weight of collagen peptide, 42.1 parts by weight of sodium hyaluronate, 27.78 parts by weight of vitamin C, 1.69 parts by weight of vitamin E, and 0.227 parts by weight of copper oxide;

Or, 8.5 parts by weight of ergothioneine, 10 parts by weight of astaxanthin, 1000 parts by weight of collagen peptide, 126.5 parts by weight of sodium hyaluronate, and 100 parts by weight of glutathione;

Or, 0.5 weight part of ergothioneine, 0.5 weight part of beta-carotene, 500 weight parts of sodium hyaluronate, 0.5 weight part of vitamin C, 200 weight parts of niacinamide, 2 weight parts of zinc citrate, and 0.01 weight part of copper oxide.

A method for preparing the ergothioneine-containing anti-aging and anti-inflammatory composition comprises: weighing raw materials according to a formula and mixing them.

A preparation comprising the anti-aging and anti-inflammatory composition containing ergothioneine and a carrier allowed by the preparation;

Optionally, the preparation form includes liquid preparation and solid preparation;

Optionally, the pharmaceutical preparation is in the form of injection, tablet, capsule, granule or paste.

Optionally, the tablet comprises a tablet core and a coating layer arranged on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside; the raw materials of the transparent coating layer include 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides; preferably, the colored coating layer is a pink coating layer, and the raw material is OPADRY IIPINK coating solution.

The anti-aging and anti-inflammatory composition containing ergothioneine, the anti-aging and anti-inflammatory composition containing ergothioneine prepared by the preparation method, or the use of the preparation in preparing anti-aging and anti-inflammatory drugs or foods;

Optionally, use in the preparation of drugs or foods for resisting skin photoaging;

Optionally, use in the preparation of anti-dermatitis drugs or foods;

Optionally, the invention is used for preparing medicines or foods for preventing skin allergy and redness.

The technical solution of the present invention has the following advantages:

1. The anti-aging and anti-inflammatory composition containing thioneine provided by the present invention comprises the following components in parts by weight: thioneine 0.5-10 parts by weight, component a 0.5-10 parts by weight; component a is any one of beta-carotene and astaxanthin; the above-mentioned prescriptions have a significant synergistic effect, can delay aging, resist skin photoaging, and also have anti-skin allergy, improve dermatitis and skin sensitive redness.

2. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the present invention also includes the following components in parts by weight: at least one of 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin, and 2-200 parts by weight of nicotinamide; the present invention has found that after adding any of the above components, the above components have the function of maintaining and ensuring the normal function of the body, and have a significant synergistic effect with the combination of components in the composition, thereby achieving better anti-aging and anti-skin allergy effects.

3. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the present invention also includes the following components in parts by weight: at least one of 50-1000 parts by weight of collagen peptide, 2-200 parts by weight of ceramide, and 5-500 parts by weight of sodium hyaluronate; the present invention has found that after adding any of the above components, the above components are raw materials for the basic components of the skin, and the combination with the components in the composition has a significant synergistic effect, which can further play a better role in delaying aging and resisting skin allergies.

4. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the present invention also includes the following components in parts by weight: 0.01-1 parts by weight of copper oxide, at least one of 2-15 parts by weight of zinc citrate; the above components have the function of maintaining and ensuring the normal function of the body, and have a significant synergistic effect with the combination of components in the composition, thereby achieving better anti-aging and anti-skin allergy effects.

5. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the present invention also includes the following components in parts by weight: 100-500 parts by weight of glutathione; the combination of the above components and the components in the composition has a significant synergistic effect, achieving better anti-aging and anti-skin allergy effects.

6. A preparation provided by the present invention comprises the anti-aging and anti-inflammatory composition containing ergothioneine, and a carrier allowed by the preparation, wherein the preparation is a tablet, and the tablet comprises a core and a coating layer arranged on the surface of the core; the core contains the anti-aging and anti-inflammatory composition containing ergothioneine; the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside in sequence; the raw material of the transparent coating layer comprises 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides; preferably, the colored coating layer is a pink coating layer, and the raw material is OPADRYIIPINK package The present invention has found that after the anti-aging and anti-inflammatory composition containing ergothioneine is pressed into a tablet core, conventional colored coating is performed, and black spots are visible in the prepared tablets, affecting the appearance. The present invention has further found that before the colored coating layer is coated, a transparent coating layer composed of 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides is first coated on the tablet core, and the transparent coating layer can isolate oxygen and moisture, hinder the reaction of the raw materials, and reduce the generation of black substances. Then, conventional colored coating is performed, and no black spots are visible in the obtained tablets.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

FIG1 is a picture of a tablet prepared in Example 10 of the present invention;

FIG. 2 is a picture of the tablets prepared in Comparative Example 1 of the present invention.

Detailed ways

The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.

Table 1

Note: The above raw materials are all powders.

Embodiment This embodiment provides the formula of embodiment 1-embodiment 11 as follows:

Table 2. Formulation

The preparation method of the above embodiment:

Weigh the required raw materials according to the above table and mix them evenly.

Embodiment 11

This embodiment provides a preparation, comprising the following steps:

(1) Using any of the anti-aging and anti-inflammatory compositions described in Examples 1 to 10 as active ingredients, a conventional process is used with or without conventional auxiliary materials to prepare a tablet core for later use.

(2) Prepare a transparent coating liquid according to the following formula: Coating powder: 95 g of hydroxypropyl methylcellulose (HPMC) and 5 g of medium chain triglyceride (MCT); mix the above coating powder with purified water at a mass ratio of 1:5.25 to prepare a transparent coating liquid. The pink coating liquid is OPADRY IIPINK coating liquid (commercially available).

(3) Using a coating machine (coating machine BGB-350F Wanshen), firstly spray the transparent coating liquid evenly on the surface of the tablet core in step (1), and then spray the pink coating liquid. The spraying process parameters are as follows: setting the coating pan speed at 2 rpm-8 rpm; setting the air inlet temperature at 50°C-100°C; setting the spray gun pressure in the drum to 0.3 MPa-0.5 MPa; setting the atomization pressure at 0.3 MPa-0.6 MPa; and setting the flattening pressure at 0.3 MPa-0.5 MPa. Finally, tablets are obtained. The tablets have a structure comprising a tablet core and a coating layer arranged on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; and the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside.

In the tablets obtained above, the weight of the tablet core is 1040 mg, the weight after a transparent coating layer is provided on the tablet core is 1053 mg, and the weight after a pink coating layer is provided on the basis is 1078 mg. Taking the active ingredient as the composition in Example 1 as a representative, the prepared tablet is shown in Figure 1, and it can be seen from Figure 1 that there are no black spots on the surface of the tablet.

Example 12

The difference between this example and Example 11 is that the coating powder includes 90 g of hydroxypropyl methylcellulose (HPMC) and 10 g of medium chain triglyceride (MCT). No black spots are visible on the surface of the prepared tablets.

Example 13

The difference between this example and Example 11 is that the coating powder is 100 g of hydroxypropyl methylcellulose (HPMC). No black spots are visible on the surface of the prepared tablets.

Comparative Example 1

This embodiment provides a preparation, comprising the following steps:

(1) Using any of the anti-aging and anti-inflammatory compositions described in Examples 1 to 10 as active ingredients, a conventional process is used with or without conventional auxiliary materials to prepare a tablet core for later use.

(2) Select OPADRY IIPINK coating solution as the pink coating solution and set aside.

(3) A coating machine (coating machine BGB-350F Wanshen) is used to evenly spray the transparent coating liquid on the surface of the tablet core in step (1), and then spray the pink coating liquid. The spraying process parameters are as follows: setting the coating pan speed at 2 rpm-8 rpm; setting the air inlet temperature at 50°C-100°C; setting the spray gun pressure in the drum to 0.3Mpa-0.5Mpa; setting the atomization pressure at 0.3Mpa-0.6Mpa; setting the flattening pressure at 0.3Mpa-0.5Mpa, and finally obtaining a tablet, wherein the tablet comprises a tablet core and a coating layer disposed on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer comprises only a colored coating layer; in the obtained tablet, the tablet core weighs 1040 mg, and the weight after a pink coating layer is disposed on the tablet core is 1078 mg. Taking the active ingredient as the composition in Example 1 as a representative, the prepared tablet is shown in FIG2 . As can be seen from Figure 2, black spots are visible on the surface of the tablet.

Experimental Example 1 Anti-light aging experiment

This experimental example investigates the effect of the composition of the present invention on anti-light aging

1. Test materials

1.1. Sample preparation information

All the examples were prepared with ultrapure water to a 20.0 mg/mL stock solution and stored at -20°C.

Positive control: Resveratrol, white powder, batch number F2121344, Shanghai Aladdin Biochemical Technology Co., Ltd., stored at -20°C. Prepared into 20.0 mg/mL stock solution with DMSO, stored at -20°C.

1.2. Experimental animals

Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450-550 μS/cm; pH was 6.5-8.5; hardness was 50-100 mg/LCaCO3), bred and provided by our company's fish farming center, the experimental animal use license number is: SYXK (Zhejiang) 2022-0004, and the breeding management complies with the requirements of the international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2023-3719-2-01.

Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 2 days post fertilization (2 dpf) were used for the efficacy evaluation of the samples' anti-photoaging efficacy.

1.3. Instruments, consumables and reagents

Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); multifunctional microplate reader (SPARK, TECAN, Austria); simulated sunlight (SOL500, Hoenle, Germany); 96-well microplate (Costar, China); 6-well plate (Zhejiang Bellanbo Biotechnology Co., Ltd., China).

CM-H2DCFDA (lot number 2456929, Invitrogen, USA); dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Austria); methylcellulose (lot number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

2. Detection Method

2dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The samples were given water-soluble (concentrations are shown in Table 2), and the positive control resveratrol concentration was 10.0μg/mL. At the same time, a normal control group and a model control group were set up, and the capacity of each well was 3mL. Except for the normal control group, the remaining experimental groups were irradiated with sunlight to induce the establishment of ultraviolet damage models. After 3 days of treatment at 28℃, 8 zebrafish were randomly selected from each experimental group and placed under a dissecting microscope for photography. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the zebrafish tail fin area was analyzed. The statistical analysis results of this indicator were used to evaluate the anti-photoaging efficacy of the samples. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. The specific statistical methods were as follows: when the samples were compared with the model control group, the independent sample T test in the parameter test was used for statistical analysis; when the samples were compared with each other, the parameter test-one-way ANOVA analysis-LSD (description, fixed and random effects, and mean value graph were checked in the options) was used for statistical analysis.

3. Test results

Table 3. Anti-photoaging effect

*, **, *** respectively indicate p<0.05, p<0.01, p<0.001 compared with the model control group. Different letters a to f have significant differences p<0.05.

As can be seen from the results of the above table, the anti-photoaging tail fin area of the model control group is significantly lower than that of the normal control group, indicating that the model control group is successfully constructed. The anti-photoaging tail fin area of the positive control group, the embodiment group and the independent raw material ergothioneine, astaxanthin, ceramide, nicotinamide, glutathione, etc. is significantly higher than that of the model control group (p < 0.05 or p < 0.01), indicating that the positive control group, the embodiment group and the independent raw material ergothioneine, astaxanthin, ceramide, nicotinamide, glutathione have the effect of anti-photoaging. At the same concentrations, the anti-photoaging tail fin area of the embodiment group is significantly higher than that of the independent raw material, indicating that there is a significant synergistic anti-photoaging effect between each component in the composition of the present invention, and further, compared between embodiments 1-10, the anti-photoaging effect of embodiment 8 is optimal, and embodiments 2-7, 9-10 are second, and example 1 is again.

Experimental Example 2 Skin Anti-Inflammation Experiment

This experimental example investigates the effect of the composition of the present invention on skin anti-inflammatory effects.

1. Test materials

1.1. Sample preparation information

All the examples were prepared with ultrapure water to a 20.0 mg/mL stock solution and stored at -20°C.

Positive control: dexamethasone, white powder, batch number C2110208, Shanghai Aladdin Biochemical Technology Co., Ltd., stored at 4°C. Prepared into 3.92 mg/mL stock solution with DMSO, ready for use.

1.2. Experimental animals

Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450-550 μS/cm; pH was 6.5-8.5; hardness was 50-100 mg/LCaCO3), bred and provided by our company's fish farming center, the experimental animal use license number is: SYXK (Zhejiang) 2022-0004, and the breeding management complies with the requirements of the international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2023-3719-2-01.

Transgenic neutrophil green fluorescent zebrafish (MPX) were bred by natural pair mating. Zebrafish aged 2dpf were used for the efficacy evaluation of the sample's skin anti-inflammatory effect.

Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 2 dpf were used to measure the relative expression of genes with anti-inflammatory effects in the skin of the samples.

1.3. Instruments, consumables and reagents

Dissecting microscope (SZX7, OLYMPUS, Japan); motorized focusing and continuously variable magnification fluorescence microscope (AZ100, Nikon, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); fully automatic sample rapid grinding machine (JXFSTPRP-24L, Shanghai Jingxin Experimental Equipment Technology Department, China); high-speed refrigerated centrifuge (Heraeus Fresco17, ThermoFisher, Germany); fully automatic nucleic acid extractor (Auto-Pure32A, Hangzhou Aosheng Instrument Co., Ltd., China); ordinary PCR amplifier (T100, BIO-RAD, Singapore); fluorescence quantitative PCR instrument (CFXConnect, BIO-RAD, Singapore); UV-visible spectrophotometer (Nanodrop2000, Thermo, USA); microplate mini centrifuge (BE-6100, Haimen Qilin Bell Instrument Manufacturing Co., Ltd., China); optical adhesive sealing film B (MSB1001, Bio-rad, USA); low-skirt 96-well plate (transparent) (HSP9601, Bio-rad, USA); 6-well plate (Zhejiang Belanbo Biotechnology Co., Ltd., China).

Sodium dodecyl sulfate (lot number L212807, Shanghai Aladdin Biochemical Technology Co., Ltd., China); methanol (lot number 20220514, Sinopharm Chemical Reagent Co., Ltd., China); dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Switzerland); methylcellulose (lot number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); ChamQ Universal SYBR qPCR Master Mix (lot number 027E2201CD, Vazyme, China); FastKing cDNA First Strand Synthesis Kit (Genomic DNA-free) (lot number Y1712, Tiangen Biochemical Technology (Beijing) Co., Ltd., China); Universal RNA Extraction TL Kit C (catalog number TL2204001643C, Foshan Aowei Biotechnology Co., Ltd., China).

2. Detection Method

2dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The samples were given water-soluble, and the positive control dexamethasone was 3.92μg/mL. At the same time, a normal control group and a model control group were set up, and the volume of each well was 3mL. Except for the normal control group, the rest of the experimental groups were given water-soluble sodium dodecyl sulfate (final concentration of 60μg/ml) to establish a zebrafish skin inflammation model. Three experiments were set up in parallel. After treatment at 28℃ for 16h, the total RNA of each group of zebrafish was extracted using UniversalRNA Extraction TL Kit C, and the total RNA concentration and purity were determined using a UV-visible spectrophotometer. 2.00μg of total RNA from zebrafish samples was taken, and 20.0μL cDNA was synthesized according to the instructions of the cDNA first-strand synthesis kit, and the expression of β-actin and il-17a/f3 genes was detected by q-PCR. β-actin was used as an internal reference for gene expression to calculate the relative RNA expression of il-17a. The statistical results were expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis. p < 0.05 indicated that the difference was statistically significant. The specific statistical methods were as follows: the sample was compared with the model control group, and the parameter test-one-way ANOVA analysis-Tukey or Dunnett was used for statistical analysis; the sample was compared with the sample, and the parameter test-one-way ANOVA analysis-LSD (description, fixed and random effects, and mean value graph were checked in the options) was used for statistical analysis.

3. Test results

Table 4. Anti-inflammatory effect

*, **, *** respectively indicate p < 0.05, p < 0.01, p < 0.001 compared with the model control group. a, b, c, d, e, f indicate statistical differences between each other at p < 0.05.

Due to the IL-17 inflammatory factor, the IL-17 secreted by skin immune cells will promote inflammation and accelerate skin aging, so the expression of the il-17a gene will reflect the situation of skin inflammation. The high expression of the il-17a gene reflects the high content of skin inflammatory factors, that is, the poor anti-inflammatory effect of the composition, and the low expression of the il-17a gene reflects the low content of skin inflammatory factors, that is, the excellent anti-inflammatory effect of the composition. From the above results, it can be seen that the relative expression of the il-17a gene in the model control group is significantly higher than that in the normal control group, indicating that the model control group is successfully constructed. Compared with the model control group, the relative expression of the il-17a gene in the positive control and the embodiment group and the raw material alone is significantly lower than that in the model control group, indicating that the positive control, the embodiment and the raw material alone have significant skin anti-inflammatory effects, and the relative expression of the il-17a gene in the embodiment group is significantly lower than that in the raw material alone, indicating that there is a significant synergistic effect between the components in the prescription of the embodiment group, which can significantly resist skin inflammation. Further, compared between embodiments 1-10, the anti-skin inflammation effect of embodiment 8 is the best, followed by embodiments 2-7, 9-10, and example 1 is the best.

Experimental Example 3: Skin Sensitivity and Redness Experiment

This experimental example investigates the effect of the composition of the present invention on skin sensitivity and redness.

1. Test materials

1.1. Sample information

The composition of each embodiment is mixed with the relevant raw materials according to the formula and then tableted or taken separately. Each tablet contains 1g of the drug and weighs 1078mg. The excipients used for tableting are conventional excipients such as microcrystalline cellulose, magnesium stearate, cross-linked polyvinylpyrrolidone or cross-linked sodium carboxymethyl cellulose, and the tablets are tableted using conventional processes.

2. Detection Method

The subjects were all healthy Chinese women aged between 30 and 55 (volunteers recruited from the society). The inclusion criteria were determined by doctors to be red on the cheeks. Five people in each group took the test, with each dose of 3 tablets, once a day, for 28 days. The test was conducted once on day 0 and day 28, recorded as D0 and D28.

The skin redness parameter was obtained by collecting facial images using Visia-CR, and then using Image-Pro-Plus image analysis software to analyze the cheek area skin a* value of the red area image under the cross-polarized light source. The smaller the value, the lighter the skin redness. The skin sensitivity redness of each group = the cheek area skin a* value corresponding to D28 - the cheek area skin a* value corresponding to D0.

The data processing method is: SPSS26.0 software is used for statistical analysis, p<0.05 indicates that the difference is statistically significant. The specific statistical methods are as follows: the samples are compared with the blank control group, and the parameter test-one-way ANOVA analysis-Tukey or Dunnett's statistical analysis is used; the samples are compared with each other, and the parameter test-one-way ANOVA analysis-LSD (check the description, fixed and random effects, and mean value graph in the options) is used for statistical analysis.

3.The test results are shown in the table below.

Table 5. Effect on sensitive skin and redness

Sensitive skin with redness sd P-value Blank control 0.7 0.36 Example 1 -0.8 0.4 *** c Example 2 -1 0.31 *** b Example 3 -0.98 0.32 *** b Example 4 -0.92 0.34 *** b Example 5 -0.92 0.3 *** b Example 6 -0.93 0.37 *** b Example 7 -0.95 0.43 *** b Example 8 -1.23 0.31 *** a Example 9 -0.93 0.44 *** b Example 10 -0.96 0.32 *** b Ergothioneine 0.55 0.32 V 0.34 0.32 Astaxanthin 0.3 0.53 Collagen Peptides -0.32 0.64 Sodium hyaluronate -0.05 0.26 Ceramide 0.1 0.45 Vc -0.26 0.59 Ve 0.13 0.64 Biotin -0.25 0.37 Nicotinamide 0.28 0.69 Copper oxide -0.24 0.59 Zinc Citrate -0.16 0.19 Glutathione 0.69 0.19

Note: *, **, *** respectively indicate p<0.05, p<0.01, p<0.001 compared with the blank control group. a, b, c indicate statistical differences between each other at p<0.05.

As can be seen from the above table, the skin sensitivity and redness of the embodiment group is significantly lower than that of the blank control group, indicating that the embodiment group has a significant effect on anti-skin sensitivity and redness, while there is no significant difference between the raw material group and the blank control, indicating that the raw material group alone has no significant effect on anti-skin sensitivity and redness, and it also shows that the components in the formula of the embodiment group have a significant synergistic effect and can significantly resist skin sensitivity and redness. Furthermore, compared with Examples 1-10, Example 8 has the best effect on anti-skin inflammation, followed by Examples 2-7, 9-10, and Example 1.

Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the protection scope of the invention.

Claims (10)

1. An anti-aging and anti-inflammatory composition containing ergothioneine is characterized by comprising the following components in parts by weight: 0.5-10 parts by weight of ergothioneine and 0.5-10 parts by weight of component a; the component a is at least one of beta-carotene and astaxanthin.

2. An anti-aging and anti-inflammatory composition containing ergothioneine according to claim 1, which is characterized by comprising the following components in parts by weight: ergothioneine 1.6 parts by weight, component a 1.7 parts by weight.

3. An anti-aging and anti-inflammatory composition containing ergothioneine according to claim 1 or 2, further comprising the following components in parts by weight: 50-1000 parts of collagen peptide, 2-200 parts of ceramide and 5-500 parts of sodium hyaluronate.

4. An anti-aging and anti-inflammatory composition containing ergothioneine according to claim 3, further comprising the following components in parts by weight: 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin and 2-200 parts by weight of nicotinamide.

5. An anti-aging and anti-inflammatory composition containing ergothioneine according to claim 3, further comprising the following components in parts by weight: 0.01-1 part by weight of copper oxide and 2-15 parts by weight of zinc citrate.

6. An anti-aging and anti-inflammatory composition containing ergothioneine according to claim 3, further comprising the following components in parts by weight: 100-500 parts of glutathione.

7. An anti-aging, anti-inflammatory composition containing ergothioneine according to any of claims 1-6, characterized by comprising the following components in parts by weight:

1.6 parts of ergothioneine, 1.7 parts of beta-carotene and 20 parts of ceramide;

Or, 0.5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 635 parts by weight of collagen peptide, and 265 parts by weight of glutathione;

Or, 10 parts by weight of ergothioneine, 0.5 part by weight of beta-carotene, 200 parts by weight of ceramide and 100 parts by weight of vitamin E;

Or, 10 parts by weight of ergothioneine, 10 parts by weight of beta-carotene, 50 parts by weight of collagen peptide and 500 parts by weight of glutathione;

Or 5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 5 parts by weight of sodium hyaluronate, 0.5 part by weight of vitamin E and 30 parts by weight of biotin;

or, ergothioneine 1 weight part, astaxanthin 0.5 weight part, ceramide 2 weight parts, vitamin C200 weight parts, biotin 5 weight parts;

or 3.2 parts by weight of ergothioneine, 5.36 parts by weight of astaxanthin, 2.6 parts by weight of ceramide, 15 parts by weight of zinc citrate and 1 part by weight of copper oxide;

Or, ergothioneine 1.69 parts by weight, beta-carotene 1.482 parts by weight, collagen peptide 834 parts by weight, sodium hyaluronate 42.1 parts by weight, vitamin C27.78 parts by weight, vitamin E1.69 parts by weight, and copper oxide 0.227 parts by weight;

Or 8.5 parts by weight of ergothioneine, 10 parts by weight of astaxanthin, 1000 parts by weight of collagen peptide, 126.5 parts by weight of sodium hyaluronate and 100 parts by weight of glutathione;

Or 0.5 part by weight of ergothioneine, 0.5 part by weight of beta-carotene, 500 parts by weight of sodium hyaluronate, 0.5 part by weight of vitamin C, 200 parts by weight of nicotinamide, 2 parts by weight of zinc citrate and 0.01 part by weight of copper oxide.

8. A process for the preparation of an anti-aging, anti-inflammatory composition comprising ergothioneine according to any of claims 1 to 7, comprising: weighing the raw materials according to the formula, and mixing.

9. A formulation comprising an anti-aging, anti-inflammatory composition comprising ergothioneine according to any of claims 1-7, and a formulation-approved carrier;

Optionally, the preparation forms comprise liquid preparation and solid preparation;

optionally, the pharmaceutical preparation comprises injection, tablet, capsule, granule or paste;

Optionally, in the tablet, a tablet core and a coating layer disposed on a surface of the tablet core are included; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer sequentially comprises a transparent coating layer and a colored coating layer from inside to outside; the transparent coating layer comprises 90-100 parts by weight of hydroxypropyl methyl cellulose and 0-10 parts by weight of medium chain triglyceride; preferably, the colored coating layer is a pink coating layer, and the raw material is OPADRY IIPINK coating liquid.

10. Use of a composition comprising ergothioneine for the delay of aging, anti-inflammatory according to any one of claims 1 to 7, a composition comprising ergothioneine for the delay of aging, anti-inflammatory prepared by the method of preparation according to claim 8, or a formulation according to claim 9 for the preparation of a medicament or food for the delay of aging, anti-inflammatory;

Optionally, in the preparation of a medicament or food for combating skin photoaging;

Optionally, in the preparation of an anti-dermatitis medicament or food;

optionally, in the preparation of a medicament or food for combating sensitive reddening of the skin.